COYA
Coya Therapeutics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- A Jun 5 Roth Capital initiates
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q2 2026: 6 added (0 new), 1 trimmed or exited.
- AnalystsBULLISH
12 of 13 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.390 → −$0.353 over 90 days. 2 up, 0 down in 30 days.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | $1.1M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $913.0K |
| JONES FINANCIAL COMPANIES LLLP | DOUBLED | $610.0K |
| ROYAL BANK OF CANADA | DOUBLED | $546.0K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | $356.9K |
| Allworth Financial LP | DOUBLED | $76.0K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | $27.9K |
| RENAISSANCE TECHNOLOGIES LLC | ADD | $409.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
13 analystsPrice is below the lowest target. Median implies +274%.Targets as of Oct 27, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 15, 2026 | BTIG REITERATE | Buy |
| Aug 24, 2026 | Roth Capital REITERATE | Buy |
| Aug 12, 2026 | Chardan Capital MAINTAIN | Buy |
| Jun 12, 2026 | Chardan Capital MAINTAIN | Buy |
| Jun 5, 2026 | Roth Capital INITIATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Apr 9, 2026 | Pavao Mark H Director | AWARD | 10,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.35 | -$0.37–-$0.33 | +0.0% | $78.6K |
| Next Q | -$0.38 | -$0.42–-$0.36 | +0.0% | $471.4K |
| Current FY | -$1.37 | -$1.42–-$1.30 | +0.0% | $1.0M |
| Next FY | -$1.92 | -$2.20–-$1.64 | -2.1% | $5.0M |
Short side
FINRA· Oct 15, 2026SecBot reports
8 filings · 0 bullish · 0 bearish · 1 mixed · 7 neutral- MIXED 8-KOct 14, 2026
Coya Therapeutics announced plans to initiate an open-label extension (OLE) of its Phase 2/3…
The FTD trial delay signals a narrower near-term pipeline catalyst, but the OLE launch and maintained cash runway reduce dilution risk. Watch for topline data from the ALSTARS double-blind phase…
- NEUTRAL 8-KOct 5, 2026
Coya Therapeutics announced full enrollment of 120 patients in its Phase 2/3 ALSTARS trial…
Full enrollment removes a key execution risk, but the stock will remain binary on topline data in early Q2 2027. Monitor for any interim analyses or safety updates before that catalyst.
- NEUTRAL 8-KSep 15, 2026
Coya Therapeutics announced that the 100th patient has been enrolled in its Phase 2/3 ALSTARS…
Monitor for topline data in early Q2 2027, which is the next major catalyst. No financial data or guidance changes here — the stock will likely trade on pipeline sentiment and broader biotech sector…
- NEUTRAL 8-KAug 11, 2026
Coya Therapeutics reported Q2 2026 financial results with a net loss of $6.6M ($-0.28/share) vs…
Monitor enrollment completion in ALSTARS Phase 2 trial (targeted 2H 2026) and initiation of Phase 2 FTD study as key catalysts. The $43.2M cash runway removes near-term financing risk but the binary…
All COYA filing & press-release reports (8)
- 8-K reportOct 14, 2026
- 8-K reportOct 5, 2026
- 8-K reportSep 15, 2026
- 8-K reportAug 11, 2026
- 8-K reportMay 12, 2026
- 8-K reportApr 2, 2026
- EFFECT reportMar 23, 2026
- S-3 reportMar 16, 2026